https://www.selleckchem.com/products/ltx-315.html
We found that with one itolizumab dose, the circulating IL-6 decreased in critically and severely ill patients, whereas in moderately ill patients the values didn't rise as compared to their low baseline levels. These findings suggest that itolizumab could be an attractive therapeutic option to decrease the negative outcome of the cytokine storm in COVID-19 patients. CECMED IIC RD-EC 179, RPCEC00000311. Registered 4 May 2020 - Retrospectively registered, http//rpcec.sld.cu/ensayos/RPCEC00000311-Sp or http//rpcec.sld.cu/trials/RPCEC00000
Aimer
Commentaire
Partagez
